Precision BioSciences, a Research Triangle Park, N.C.-based genome editing company, closed a $25.6m Series A financing.
The round was led by venBio with participation from Fidelity Biosciences, Amgen Ventures, Baxter Ventures, Osage University Partners, the Longevity Fund, and two public market investors. Robert Adelman of venBio and Ben Auspitz of Fidelity Biosciences will join Precision’s Board in conjunction with the funding.
The company intends to use the funds to develop the next-gen genome editing platform and accelerate the development of its genome-edited product pipeline.
Led by Chief Executive Officer Matthew Kane and Chief Scientific Officer Derek Jantz, Precision BioSciences leverages the ARCUS genome editing technology to develop specific nucleases that can insert, remove, and modify DNA at essentially any location in a complex genome.